Market Intelligence, Clinical Progress, and High-Purity Reagents for Iron Metabolism Disorders and Anemia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HAMP/hepcidin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HAMP (Hepcidin) Recombinant Protein Properly folded with 4 disulfide bonds, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified by Mass Spec. |
View HAMP Products |
| Receptor | SLC40A1 (Ferroportin) ECD-Fc Protein Human/Mouse/Cyno orthologs available. Sequence Verified. |
View SLC40A1 Products |
| Gene Delivery | HAMP Promise-ORF / Lentivirus Full-length ORF with native signal peptide for secreted expression. |
View HAMP Products |
| Benchmark Ab | Anti-HAMP Neutralizing Antibody Recombinant positive control for binding inhibition assays. |
View HAMP Products |
| Validator | HAMP siRNA Set For knockdown verification and specificity controls. |
View HAMP Products |
| Upstream Regulator | BMP6 Protein Key inducer of hepcidin expression. For pathway studies. |
View BMP6 Products |
| Modulator | TMPRSS6 (Matriptase-2) Negative regulator of hepcidin. Protease domain for inhibitor screening. |
View TMPRSS6 Products |
| Related Target | IL6 (Interleukin 6) Key inflammatory cytokine driving HAMP overexpression. |
View IL6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Correct Disulfide Bond Formation (4 disulfides in 25 aa) | HEK293 Expressed, Oxidative refolding protocol, Mass Spec verified molecular weight |
| Ferroportin Binding & Internalization | SLC40A1 ECD-Fc proteins with native glycosylation (>95% purity) for SPR/BLI; Lentivirus for stable cell line construction |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno HAMP ortholog proteins with species-specific epitope preservation |
| Functional Validation | Validated siRNA included for specificity checks; Benchmark neutralizing antibodies |
Global Clinical Landscape & Future Outlook
The race for hepcidin pathway modulators is bifurcating between hepcidin mimetics (for iron overload disorders like β-thalassemia and polycythemia vera) and hepcidin inhibitors (for anemia of inflammation/chronic disease). Protagonist Therapeutics leads with PTG-300, an injectable hepcidin mimetic demonstrating superior iron restriction compared to endogenous peptide. Meanwhile, antibody approaches targeting the hepcidin-ferroportin axis are advancing for inflammatory indications, with players like Eli Lilly and AbbVie. As first-generation peptide therapeutics establish proof-of-concept, the next wave targets oral bioavailability through small molecule BMP/SMAD pathway inhibitors and engineered peptide variants with enhanced stability. The critical unmet need remains precise iron redistribution without systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Hepcidin Mimetic | Protagonist Therapeutics (PTG-300) | Polycythemia Vera, β-Thalassemia | Ferroportin Internalization Assay (Need correctly folded HAMP with 4 disulfides) |
| Anti-Hepcidin mAb | Novartis, Eli Lilly, AbbVie | Anemia of Inflammation / Chronic Disease | Epitope Mapping (Need full-length HAMP vs. truncated variants) |
| BMP Inhibitor (Small Mol) | Disc Medicine, Silence Therapeutics | Hereditary Hemochromatosis | Pathway Reporter Assay (Need BMP6/HAMP cascade reagents) |
| Ferroportin Modulator | Vifor Pharma | Iron Deficiency | Binding Competition Assay (Need HAMP/SLC40A1 heterodimer validation) |
| siRNA | Alnylam | Iron Overload Disorders | Knockdown Validation (Need HAMP siRNA and ORF) |
Assay Development Considerations
Hepcidin is a 25-amino acid peptide containing four critical disulfide bonds that define its structure and ferroportin-binding affinity. Proper oxidative folding is the primary quality differentiator—misfolded variants show >100-fold reduced binding. TarMart provides sequence-verified, endotoxin-controlled HAMP proteins produced in HEK293 cells to ensure native disulfide patterns.
For inhibitor development, cross-species reactivity is essential. While human and cynomolgus hepcidin share 100% sequence identity, murine models require careful validation due to species-specific differences in ferroportin binding kinetics.
Live HAMP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: